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We describe ﬁve female carriers of the FMR1 premutation who presented with symptoms of tremor and ataxia
and who received a diagnosis of deﬁnite or probable fragile-X–associated tremor/ataxia syndrome (FXTAS). Unlike
their male counterparts with FXTAS, none of the women had dementia. Females had not been reported in previous
studies of FXTAS, suggesting that they may be relatively protected from this disorder. Brain tissue was available
from one of the ﬁve subjects, a women who died at age 85 years; microscopic examination revealed intranuclear
neuronal and astrocytic inclusions, in accord with the ﬁndings previously reported in males with FXTAS. The work-
up of families with the FMR1 mutation should include questions regarding neurological symptoms in both older
male and female carriers, with the expectation that females may also manifest the symptoms of FXTAS, although
more subtly and less often than their male counterparts.
Individuals who carry premutation alleles (55–200CGG
repeats) of the fragile-X–mental retardation 1 (FMR1
[MIM 309550]) gene are usually unaffected by the cog-
nitive impairment associated with fragile-X syndrome
(Reiss et al. 1993). However, ∼20%–25% of carriers
have prominent ears, mild psychiatric symptoms such as
anxiety or social phobia, and/or premature ovarian fail-
ure (Sobesky 1996; Franke et al. 1998; Riddle et al. 1998;
Allingham-Hawkins et al. 1999; Murray et al. 2000).
Moreover, a subgroup of older adult male carriers de-
velops a progressive neurological syndrome, fragile-X–
associated tremor/ataxia syndrome (FXTAS). Onset is
typically at age 50–70 years and includes progressive
intention tremor and/or gait ataxia and mild parkinson-
ism (Hagerman et al. 2001; Berry-Kravis et al. 2003;
Jacquemont et al. 2003, 2004a, 2004b; Leehey et al.
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2003). More variable features include memory and ex-
ecutive-function deﬁcits, with a gradual cognitive decline
to dementia in some individuals; loss of vibration and
tactile sensation and reﬂexes in the distal lower extremi-
ties; and psychiatric symptoms, including anxiety, mood
lability, and depression (Hagerman et al. 2001; Jacque-
mont et al. 2003, 2004a). Associated radiological ﬁnd-
ings include global brain atrophy and white-matter dis-
ease, with a characteristic enhancement of T2 signal
intensity in themiddle cerebellar peduncles (MCPs) (Brun-
berg et al. 2002). Neuropathological examination of
four males who died with FXTAS identiﬁed eosinophilic,
intranuclear inclusions in 5%–40%of neurons and 30%–
50% of astroglia throughout the cortex and cerebellum,
with the exception of Purkinje cells, where no inclusions
were observed (Greco et al. 2002). These intranuclear
inclusions are ubiquitin positive but tau, synuclein, and
polyglutamine negative, differentiating them from the in-
tranuclear-inclusion disorders associated with increased
CAG repeats (SCAs, HD, etc.) (Greco et al. 2002; Hag-
erman et al. 2003a). The abnormal white-matter signal
seen in the MCPs on magnetic resonance imaging (MRI)
corresponds to spongiform changes associated withmild
axonal and myelin loss (Greco et al. 2002). The cause of
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Table 1
Summary of Clinical and Molecular Findings
CHARACTERISTIC
PATIENT
1 2 3 4 5
Current age (years) 67 57 85 62 74
Full-scale IQ 126 99 100 111 87
Verbal IQ 130 103 104 110 88
Performance IQ 116 94 94 111 86
Age at tremor onset (years) 41 30 82 52 71
Age at ataxia onset (years) 59 37 79 60 71
CGG repeat 18, 90 29, 93 29, 87 18, 90 30,78
FMRP levela 89 96 80 70 90
Activation ratiob .51 .35 .53 .5 .21
mRNA level 3.25.55 4.6.29 1.40.07 2.52.27 2.6.04
MRI result  MCP sign No MCP sign Pacemaker Pacemaker No MCP sign
FXTAS diagnosis Deﬁnite Probable Deﬁnite Probable Probable
a Percentage of lymphocytes positive for FMRP by immunocytochemical staining, as described by Tassone
et al. (2000b).
b Activation ratio calculated as described by Tassone et al. (1999).
the inclusions and the other neuropathological changes is
thought to be related to a toxic effect of the elevated
levels of the expanded-CGG-repeat mRNA, present in
individuals with the premutation but not in those with
the fully methylated full mutation (Tassone et al. 2000a,
2000b, 2001). Thus far, FXTAS has been reported only
in males with the FMR1 premutation.
Here, we present ﬁve female carriers of the FMR1
premutation who were identiﬁed either through family
studies or as patients seen at our clinic with a primary
complaint related to the clinical features of FXTAS; we
document the presence of inclusions in one patient for
whom we performed postmortem neuropathological
studies.
Cognitive testing was performed in all ﬁve patients,
and results are presented in table 1. None of the women
demonstrated dementia. Patient 1 has a superior IQ.
Patient 1 is a 67-year-old nun with a Ph.D. who ex-
perienced onset of intention tremor at age 41 years. The
tremor was ﬁrst noticed in her right hand when she was
eating, and it gradually worsened. By age 47 years, it
was hard for her to drink from a cup without spilling.
By age 50 years, she found it impossible to write more
than one or two words. Head tremors and ataxia de-
veloped in her 50s, resulting in frequent falling.Naldolol
and clonazepamwere prescribed for her tremor andwere
found to be helpful. At age 65 years, she began to notice
leg aches, although a work-up for peripheral vascular ab-
normalities showed normal results. Menopause occurred
at age 46 years; the patient has since begun hormone-
replacement therapy (HRT).
The patient’s neurological examination revealed a
marked intention tremor with terminal dysmetria bilat-
erally, more pronounced in her left arm. She also dis-
played a postural tremor and an intermittent resting
tremor. Deep tendon reﬂexes were 1 in the upper ex-
tremities but could not be elicited in the lower extremi-
ties. She had decreased sensation to pinprick and vi-
bration in the distal lower extremities. She was unable
to tandem walk. Her plantar reﬂexes were ﬂexor bi-
laterally. She had a mild rigidity in the upper extremities
(table 1).
Axial T2–weighted images at age 67 years demon-
strated mildly increased T2-signal intensity in theMCPs,
right greater than left, and in the paramedian pons. The
changes were most conspicuous on inversion recovery
sequences (ﬁg. 1). Also noted was a slightly increased
T2-signal intensity in subependymal white matter of the
frontal and parietal hemispheres (ﬁg. 1).
Patient 2 is a 57-year-old teacher and grandmother of
children who have fragile-X syndrome. She experienced
onset of an intermittent tremor in her 30s and progres-
sive balance problems beginning at age 37 years, which
caused her to fall. Her gait difﬁculties gradually wors-
ened over the next 15 years, requiring the use of a wheel-
chair by age 51 years. For the past 4 years, she has been
conﬁned to a wheelchair and can only ambulate inde-
pendently for a few steps. She has been dysarthric for
the past 6 years and had frequent episodes of dysphagia,
with solids and liquids, over the past 3 years. She de-
veloped signiﬁcant bowel and bladder incontinence in
her 30s, leading to a colostomy, at age 43 years, after
she had completely lost control of bowel function. Spon-
dylosis was diagnosed at age 32 years. From her 40s
onward, she experienced chronic back spasms and pain
in all four extremities; more recently, she has had some
complaints of mildly decreased sensation and burning
paresthesias in both feet.
The patient’s medical history includes bilateral carpal
tunnel syndrome, ﬁbromyalgia, cataracts, chronic daily
headaches, hypertension, and type II diabetes, controlled
by diet. She also has strabismus with a left-eye amblyo-
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Figure 1 Axial inversion recovery images of patient 1. A, Increased signal intensity demonstrated in the MCPs bilaterally, right greater
than left. B and C, Increased signal intensity in the paramedian pons and at the pontomesencephalic junction. D, Mildly increased signal intensity
in subependymal white matter of the frontal lobes.
Figure 2 Ubiquitin-positive intranuclear inclusions from the hip-
pocampus of patient 3.
pia. Previous psychiatric diagnoses have included hy-
peractivity, both as a child and an adult, and postpar-
tum depression.
The patient’s neurologic examination included a mild
left-sided exotropia with decreased vision in the left eye,
but with no signiﬁcant nystagmus. She had dysarthria,
an intermittent intention tremor with decreased motor
coordination, and dysmetria in all four extremities.Mus-
cle strength and tone were normal. Deep-tendon reﬂexes
were normal in the upper extremities and at the patellae
but could not be elicited at the ankles. Plantar reﬂexes
were ﬂexor. She had mildly decreased sensation to pin-
prick and temperature in a symmetric stocking-glove dis-
tribution, with preserved vibration sense. Gait was wide-
based, with an inability to tandem walk. Performance on
Rhomberg testing was unsteady with eyes open.
MRI of the brain at age 57 years demonstrated no
alteration in whitematter–T2 signal intensity in theMCPs
or cerebral hemispheres. There wasmild cerebral cortical
volume loss and mild prominence in size of the lateral
ventricles (table 1).
Patient 3 was an 85-year-old Hispanic female who
worked as a community social worker until retiring at
age 65 years and raised two children and two grand-
childrenwith fragile-X syndrome. Shewas diagnosedwith
anxiety and depression at age 75 years and was treated
with ﬂuoxetine, although she had experienced anxiety
for many years prior to diagnosis. She had a mild ataxia
and began using a cane at age 79 years because of gait
unsteadiness. Falling episodes led to a fractured right
femur at age 81 years and a fractured left hip at age 84
years. Intention tremor and extremity weakness began at
age 82 years and interfered with activities of daily living.
She died at age 85 years and 11 months, after compli-
cations from gastrointestinal surgery for ileus (table 1).
An MRI was not performed during the patient’s life
because of the presence of a pacemaker. A postmortem
MRI was done on her brain, following 2 weeks of ﬁxa-
tion in 10% formalin. There was no alteration in T2-
signal intensity in the MCPs. There was mildly increased
signal intensity in subependymal and deep white matter
of the frontal and parietal lobes, and there was mild
cerebral-cortical volume loss.
Gross examination of the brain, which weighed 980 g,
showedmild parietal gyral atrophy and amarkeddecrease
in ventricular size, suggesting agonal brain edema. Histo-
logical studies of hematoxylin and eosin stain demon-
strated eosinophilic intranuclear inclusions inneuronsand
astroglia throughout the cerebrum and cerebellum, with
the exception of Purkinje cells (ﬁg. 2). Ependymal and
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subependymal cells and epithelial cells of the choroid
plexus showed the intranuclear inclusions. Immunocyto-
chemical staining of the inclusions was positive for ubi-
quitin and negative for tau- and a-synuclein. The inclu-
sions were negative for silver and PAS staining.
Patient 4 is the 62-year-old sister of patient 1. She has
raised nine children, and all but one are affected with
fragile-X syndrome.
Patient 4 developed an intermittent intention tremor
at age 52 years that gradually worsened and began in-
terfering with eating at age 60 years. Intermittent head
tremor began at age 57 years, but it is usually subtle and
not noticed by others. Over the past year, she developed
a tremor at rest in her hands, and her handwriting be-
came illegible.
Numbness in her right foot began at age 52 years,
after ankle surgery, and appeared in her left foot at age
59 years. Patient 4 complained of muscle pain in her
legs approximately four times per week for the past 5
years and weakness in her arms for the past 2–3 years.
More frequent falling began 1.5 years ago, and she now
requires handrail support when using stairs. Memory
deﬁcits have occurred for the past 2–3 years, but she felt
this to be consistent with her age.
Medical history includes hyperthyroidism treatedwith
surgery, bradycardia and arrhythmias consistent with
sick-sinus syndrome (pacemaker implanted at age 56
years), pericarditis, glaucoma, status post surgery for
carpal tunnel syndrome, and hypertension treated for
the past 10 years with hydrochlorothiazide.
On examination, she had tremor at rest, when postur-
ing, and with action; tremor in the left hand was worse
than the right. Head tremor was also visible. Deep-tendon
reﬂexes were 1 in the upper extremities and could not
be elicited in the lower extremities. In the lower extrem-
ities, she had decreased sensation to pin prick and vibra-
tion (table 1).
Patient 5 is a 74-year-old woman who ﬁrst developed
light-headedness and unsteady gait at age 71 years, re-
sulting in frequent falls. At about the same time, she
noticed tremor in her hands when carrying food on a
plate and, later, when writing, embroidering, and doing
puzzles. These symptoms were accompanied by numb-
ness in her lower extremities. Her symptoms gradually
worsened, leading to her ﬁrst evaluation at age 74 years.
At that time, she reported some improvement of her
tremor while taking inderol and signiﬁcant improvement
while taking primidone.
On examination, she had a mild intention tremor,
which was worse on the right side. She also had mild
parkinsonism, characterized by mild bradykinesia, posi-
tive retropulsion, upper-extremity rigidity that was
worse on the right side, and mild dystonia involving
her neck muscles. Lower extremities had symmetrical
reﬂexes but decreased sensation to pin prick and vibra-
tion. Tandem walking demonstrated ataxia, and gait
was mildly broad based.
This report describes ﬁve women, two of them sisters,
with deﬁnite or probable FXTAS without dementia. Pre-
vious published reports of FXTAS have not found in-
volvement in women, suggesting that they are far less
frequently affected than males (Hagerman et al. 2001;
Brunberg et al. 2002; Leehey et al. 2002; Berry-Kravis
et al. 2003; Jacquemont et al. 2003, 2004a). In the study
by Jacquemont et al. (2004b), a direct comparison of 59
females with the premutation with 34 control individuals
did not demonstrate signiﬁcant symptoms of FXTAS, ei-
ther by questionnaire responses or by standardized neu-
rological examination. In addition to the presence of the
FMR1 premutation, criteria for a “deﬁnite” diagnosis of
FXTAS include intention tremor and/or ataxia and in-
creased T2-signal intensity in the MCPs (Jacquemont et
al. 2003). Patient 1 met these criteria.
Neurohistological studies of patient 3 demonstrated
eosinophilic inclusions in neurons and astrocytes that
were identical to those previously reported in males with
FXTAS. These inclusions have been seen in all (9/9) cases
examined to date of males who have died with FXTAS,
but they have not been found in controls. One female
with the premutation, who died at age 67 years but
without any clinical or radiological features of FXTAS,
did not have inclusions (Hagerman et al. 2003a). The
inclusions appear to be pathognomonic of FXTAS; when
seen with clinical ﬁndings of tremor and/or ataxia, this
meets diagnostic criteria for deﬁnite FXTAS (Hagerman
and Hagerman 2004 [in this issue]). Therefore, patient
3 meets the criteria for deﬁnite FXTAS.
The diagnosis of “probable” FXTAS does not require
MCP involvement but does require the presence of tremor
and ataxia. In the study by Jacquemont et al. (2003),
nearly one-half of the cases did not have the MCP in-
volvement. Patients 2, 4, and 5 met the criteria for prob-
able FXTAS, each having both tremor and ataxia.
In controlled studies, females with the premutation
have not had signiﬁcant neurological symptoms, com-
pared with controls (Berry-Kravis et al. 2003; Jacque-
mont et al. 2004b). The relative lack of symptomatol-
ogy in females may be related to the presence of the
second X chromosome and random X inactivation, so
that a portion of the cells in the brain have the active,
normal FMR1 gene. Alternatively, a sex-speciﬁc effect,
perhaps related to estrogen, may be protective in fe-
males. Patients 1, 2, and 4 received postmenopausal
HRT, whereas patients 3 and 5 did not.
We have hypothesized that FXTAS—as well as the
inclusions themselves—is caused by a toxic gain of func-
tion of the elevated FMR1 mRNA (Hagerman et al. 2001,
2003b; Greco et al. 2002;Hagerman andHagerman2004
[in this issue]). Further support for the toxic gain-of-func-
tion model comes from animal studies, wherein CGG
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repeats, placed either in the mouse FMR1 homologue
(Fmr1) or in a heterologous gene in Drosophila, give
rise to neural-cell inclusions (Jin et al. 2003; Willemsen
et al. 2003).
Positively skewed X inactivation, with the normal al-
lele preferentially carried on the active X chromosome,
could mitigate the toxic effects of elevated mRNA; how-
ever, none of the patients in the current study were
skewed toward the normal, active allele. Skewing toward
activation of the premutation X has been seen in two
sisters with spastic paraparesis and extensive white-mat-
ter disease, including theMCP involvement. This presen-
tation may be a severe variant of FXTAS (Tassone et al.
2002).
These ﬁve females with FXTAS demonstrate a broad
spectrum of symptomatology, ranging from relatively se-
vere disease that is slowly progressive from mid-adult-
hood (patient 1) to a mild case (patient 3) beginning late
in life (age 79 years). The ﬁve women all demonstrated
a clinical course that was typical of males with FXTAS
and included intention tremor, ataxia, parkinsonism, and
peripheral neuropathy. However, none of these female
patients had dementia (which is seen in ∼20% of males
with FXTAS [Jacquemont et al. 2004a]), and all IQs
were either normal or high, although mild executive-
function deﬁcits were seen in patients 2 and 3.
We recommend that families with the FMR1mutation
be studied for the presence of FXTAS in both male and
female grandparents and in mothers who are carriers of
the FMR1 premutation. The expectation is that female
carriers (1/260 in the general population) will probably
manifest these symptoms more subtly and less often than
their male counterparts.
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